Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis

奎硫平 奥氮平 阿立哌唑 齐拉西酮 心理学 中止 利培酮 氟西汀 安慰剂 医学 内科学 精神科 药理学 精神分裂症(面向对象编程) 受体 替代医学 病理 血清素
作者
Nicolás A. Núñez,Boney Joseph,Mehak Pahwa,Rakesh Kumar,Manuel Gardea‐Resendez,Larry J. Prokop,Marin Veldić,Ashok Seshadri,Joanna M. Biernacka,Mark A. Frye,Zhen Wang,Balwinder Singh
出处
期刊:Journal of Affective Disorders [Elsevier BV]
卷期号:302: 385-400 被引量:72
标识
DOI:10.1016/j.jad.2021.12.134
摘要

To compare the efficacy and discontinuation of augmentation agents in adult patients with treatment-resistant depression (TRD). We conducted a systematic review and network meta-analyses (NMA) to combine direct and indirect comparisons of augmentation agents.We included randomized controlled trials comparing one active drug with another or with placebo following a treatment course up to 24 weeks. Nineteen agents were included: stimulants, atypical antipsychotics, thyroid hormones, antidepressants, and mood stabilizers. Data for response/remission and all-cause discontinuation rates were analyzed. We estimated effect-size by relative risk using pairwise and NMA with random-effects model.A total of 65 studies (N = 12,415) with 19 augmentation agents were included in the NMA. Our findings from the NMA for response rates, compared to placebo, were significant for: liothyronine, nortriptyline, aripiprazole, brexpiprazole, quetiapine, lithium, modafinil, olanzapine (fluoxetine), cariprazine, and lisdexamfetamine. For remission rates, compared to placebo, were significant for: thyroid hormone(T4), aripiprazole, brexpiprazole, risperidone, quetiapine, and olanzapine (fluoxetine). Compared to placebo, ziprasidone, mirtazapine, and cariprazine had statistically significant higher discontinuation rates. Overall, 24% studies were rated as having low risk of bias (RoB), 63% had moderate RoB and 13% had high RoB.Heterogeneity in TRD definitions, variable trial duration and methodological clinical design of older studies and small number of trials per comparisons.This NMA suggests a superiority of the regulatory approved adjunctive atypical antipsychotics, thyroid hormones, dopamine compounds (modafinil and lisdexamfetamine) and lithium. Acceptability was lower with ziprasidone, mirtazapine, and cariprazine. Further research and head-to-head studies should be considered to strengthen the best available options for TRD.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
CipherSage应助小雨采纳,获得10
1秒前
1秒前
AAA1798发布了新的文献求助10
1秒前
干净溪流发布了新的文献求助10
1秒前
qiujinlan完成签到,获得积分10
3秒前
wanci应助猪猪hero采纳,获得10
3秒前
4秒前
4秒前
ZXD1989完成签到 ,获得积分10
4秒前
欢呼的hhh完成签到,获得积分10
5秒前
wy.he应助肖雪依采纳,获得10
5秒前
汉尼拔·萝卜完成签到,获得积分20
6秒前
6秒前
6秒前
6秒前
眼睛大雨筠应助张振宇采纳,获得200
7秒前
狂野忆文发布了新的文献求助10
8秒前
风雪丽人完成签到,获得积分10
8秒前
狂野忆文发布了新的文献求助10
8秒前
争取不秃顶的医学僧完成签到,获得积分10
8秒前
狂野忆文发布了新的文献求助10
9秒前
狂野忆文发布了新的文献求助10
9秒前
狂野忆文发布了新的文献求助10
9秒前
狂野忆文发布了新的文献求助10
9秒前
狂野忆文发布了新的文献求助10
9秒前
橘笙完成签到,获得积分10
10秒前
写作业发布了新的文献求助10
10秒前
狂野忆文发布了新的文献求助10
10秒前
xiha西希完成签到,获得积分10
10秒前
狂野忆文发布了新的文献求助10
10秒前
狂野忆文发布了新的文献求助10
10秒前
天天快乐应助快乐小熊猫采纳,获得10
10秒前
华仔应助liuyuh采纳,获得10
11秒前
11秒前
li完成签到,获得积分10
13秒前
量子星尘发布了新的文献求助10
13秒前
angel完成签到,获得积分10
14秒前
14秒前
15秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969574
求助须知:如何正确求助?哪些是违规求助? 3514435
关于积分的说明 11173986
捐赠科研通 3249755
什么是DOI,文献DOI怎么找? 1794979
邀请新用户注册赠送积分活动 875537
科研通“疑难数据库(出版商)”最低求助积分说明 804844